<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00847938</url>
  </required_header>
  <id_info>
    <org_study_id>CHD066-08</org_study_id>
    <nct_id>NCT00847938</nct_id>
  </id_info>
  <brief_title>Comparision of Different Dose of Neostigmine at Advanced Decurarization</brief_title>
  <acronym>NEODEC</acronym>
  <official_title>Randomized, Controlled, Double-blind, Prospective Study, Comparing Different Doses of Neostigmine at Advanced Decurarization .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuromuscular blockers (NMB) are currently used in anesthesia. Residual paralysis (RP) due to
      NMB is responsible for respiratory disorders after extubation. Neuromuscular blockade is
      monitored by train-of-four (TOF) stimulation at the adductor pollicis. To exclude a RP a
      mechanomyographic TOF ratio of 0.9 is mandatory. But mecanomyography is not available in
      clinical routine. Acceleromyography is the most currently monitoring available in daily
      practice but it has been proved that an acceloromyographic (AMG) TOF ratio of 1.0 is
      necessary to exclude a RP. The incidence of RP in recovery room is underestimated. So to
      perform a safe extubation, reversal of the neuromuscular blockade is necessary when an AMG
      TOF ratio has not reached 1.0. Reversal of neuromuscular blockade is achieved with
      neostigmine. The recommended dose is 0.04 mg/kg. The administration of neostigmine causes
      parasympathomimetic effects which has to be reversed with atropine. When neuromuscular
      blockade is light (AMG TOF ratio of 0.4 which corresponds to the absence of fade at the
      visual evaluation of the TOF), a low dose of neostigmine might be sufficient with less side
      effects expected. The goal of the study is to compare the delay between a light neuromuscular
      block and an AMG TOF ratio of 1.0 for three neostigmine regimens of neostigmine 0.04, 0.02,
      0.01 mg/kg with atropine respectively 0.02, 0.01, 0.005 mg/kg and a placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mesure of the train of four, vitals signs, electrocardiogramm, bispectral index of Electro-encephalogram measuring the depth of anesthesia</measure>
    <time_frame>inclusion, anesthesia, anesthesia +6 hours, anesthesia + 12 hours, anesthesia +24h, anesthesia +48 h</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neostigmine 0.04 mg.kg associated with atropine 0.02 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neostigmine 0.02 mg.kg associated with atropine 0.01 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neostigmine 0.1 mg.kg associated with atropine 0.05 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no injection of neostigmine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neostigmine</intervention_name>
    <description>0.04 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neostigmine</intervention_name>
    <description>0.02 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neostigmine</intervention_name>
    <description>0.01 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient &gt; 18 years

          -  informed consent signed

          -  Patient undergoing any type of scheduled surgery under general anesthesia for which
             curarization with eventually a maintenance is indicated

          -  ASA score between I to III

        Exclusion Criteria:

          -  patient &gt; 75 years and &lt; 18 years

          -  body mass index &gt; 32 mg/m²

          -  neurology disease, neuromuscular or muscular disease

          -  peripheral neuropathy

          -  coronary heart disease

          -  asthma

          -  familial history of malign hyperthermia

          -  difficulty of intubation and ventilation

          -  full stomach

          -  known or suspected allergy to one of the study drug

          -  mecanique obstruction of digestive or urinary tract

          -  open-angle glaucoma

          -  patient with risk of urinary retention linked to urethra-prostatic disorder

          -  concomittant medication with a influence known on neuromuscular (aminosid,
             anti-convulsif and corticosteroid

          -  child bearing women or nursing mother

          -  no affiliation at a social security
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florent Capron, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD Vendee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2009</study_first_submitted>
  <study_first_submitted_qc>February 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <last_update_submitted>November 30, 2009</last_update_submitted>
  <last_update_submitted_qc>November 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Florent Caperon (medical doctor)</name_title>
    <organization>CHD Vendée</organization>
  </responsible_party>
  <keyword>neostigmine</keyword>
  <keyword>neuromuscular blocking agent</keyword>
  <keyword>train of four</keyword>
  <keyword>anesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

